Please login to the form below

Not currently logged in
Email:
Password:

Dermavant

This page shows the latest Dermavant news and features for those working in and with pharma, biotech and healthcare.

Urovant slips on phase 3 incontinence drug data

Urovant slips on phase 3 incontinence drug data

Others cued up for results include phase 3 trials of Myovant’s relugolix in uterine fibroids, endometriosis and prostate cancer, and Dermavant’s tapinarof in psoriasis.

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Dermavant strengthens executive team Dermavant strengthens executive team

    Dermavant Sciences, a biopharmaceutical company focused on delivering therapies for dermatologic conditions, has bolstered its executive team with the addition of four new hires. ... Peterson, who previously worked at Sienna Biopharmaceuticals as its

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics